CoChat

Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019

Haston, Julia C., Hwang, Jimee, Tan, Kathrine R. · 2019 · MMWR. Morbidity and Mortality Weekly Report
Cited by 49

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm6846a4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 16

  1. CDC. Yellow book 2018: health information for international travel. New York, NY: Oxford University Press; 2017.
  2. Mace KE, Arguin PM, Lucchi NW, Tan KR. Malaria surveillance—United States, 2016. MMWR Surveill Summ 2019;68(No. SS-5). · DOI
  3. Hill, 2006, Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I., Am J Trop Med Hyg, 75, 402, 10.4269/ajtmh.2006.75.402 · DOI · Paper page
  4. Rueangweerayut, 2017, Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol Variant) versus G6PD-normal volunteers., Am J Trop Med Hyg, 97, 702, 10.4269/ajtmh.16-0779 · DOI · Paper page
  5. Baird, 2018, Tafenoquine for travelers’ malaria: evidence, rationale and recommendations., J Travel Med, 25, 10.1093/jtm/tay110 · DOI
  6. Shanks, 2001, A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria., Clin Infect Dis, 33, 1968, 10.1086/324081 · DOI · Paper page
  7. Hale, 2003, A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum., Clin Infect Dis, 36, 541, 10.1086/367542 · doi:10.1086/367542
  8. Nasveld, 2010, Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects., Antimicrob Agents Chemother, 54, 792, 10.1128/AAC.00354-09 · doi:10.1128/aac.00354-09
  9. Dow, 2014, A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area., Malar J, 13, 49, 10.1186/1475-2875-13-49 · doi:10.1186/1475-2875-13-49
  10. McCarthy, 2018, Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled Phase 1b study., Clin Infect Dis, 69, 480, 10.1093/cid/ciy939 · doi:10.1093/cid/ciy939
  11. Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study., Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
  12. Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria., N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
  13. Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria (DETECTIVE Phase III)., N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
  14. Mueller, 2007, Plasmodium malariae and Plasmodium ovale—the “bashful” malaria parasites., Trends Parasitol, 23, 278, 10.1016/j.pt.2007.04.009 · DOI · Paper page
  15. Shimizu, 2015, Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers—a retrospective analysis., Travel Med Infect Dis, 13, 235, 10.1016/j.tmaid.2014.11.005 · DOI
  16. Faucher, 2013, Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008–2010)., J Travel Med, 20, 134, 10.1111/jtm.12009 · doi:10.1111/jtm.12009

Cited by

See all 49

Metadata

Authors
Haston, J. C., Hwang, J., & Tan, K. R.
Venue
MMWR. Morbidity and Mortality Weekly Report
Published
2019-11-22
Volume
68
Issue
46
Pages
1062-1068
ISSN
  • 0149-2195
  • 1545-861X
Cited by
49
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019. https://app.cochat.ai/papers/10.15585/mmwr.mm6846a4
The paper
Haston, J. C., Hwang, J., & Tan, K. R. (2019). Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria—United States, 2019. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6846a4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.